Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Rises By 39.0%

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 792,779 shares, an increase of 39.0% from the February 26th total of 570,220 shares. Based on an average daily trading volume, of 442,572 shares, the short-interest ratio is currently 1.8 days. Approximately 20.3% of the company’s stock are sold short.

Oragenics Trading Down 4.9%

Oragenics stock opened at $0.50 on Tuesday. The firm has a market capitalization of $2.19 million, a price-to-earnings ratio of -0.04 and a beta of 1.09. The firm’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $0.97. Oragenics has a 1-year low of $0.50 and a 1-year high of $9.60.

Institutional Investors Weigh In On Oragenics

Several institutional investors have recently bought and sold shares of the stock. DRW Securities LLC lifted its stake in Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after acquiring an additional 50,900 shares in the last quarter. Bank of America Corp DE boosted its holdings in Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after acquiring an additional 15,338 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Oragenics in the 4th quarter worth $26,000. Sabby Management LLC purchased a new stake in shares of Oragenics in the third quarter valued at about $77,000. Finally, Clear Street LLC purchased a new stake in shares of Oragenics in the second quarter valued at about $270,000. Institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.